Five year outcomes of Phase II NADIM trial, summarised by Jarushka Naidoo

Jarushka Naidoo shared a post on X:

“5yr outcomes Ph II NADIM trial: –
– 5yr PFS 65% OS 69.3%
– pCR: 5yr PFS 92% OS 95.8%; nonpCR 60%&66%
– ctDNA clearance: 5yr PFS 85.2% OS 92.3%

‘patients disease-free beyond 3yrs, could be considered cured’
Powerful conclusion, powerful trial.”

Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

Authors: Mariano Provencio, et al.

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.